the secondary end point was achieved, ie statistically significant improvement in progression free survival in the liver, so why wouldn't this result in higher utilisation as salvage therapy ?
this company has had 42 consecutive quarters of profit growth, with zero debt, by use as salvage therapy all along, not as first line therapy. so the failure of the primary end point does NOT mean all is lost, unlike what the naysayers think !
CAFA on Sirtex, page-18
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.8¢ |
Change
0.003(1.43%) |
Mkt cap ! $75.34M | |||
| Open | High | Low | Value | Volume |
| 17.8¢ | 17.8¢ | 17.5¢ | $9.047K | 50.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 7293686 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1399496 | 11 |
View Market Depth
| Last trade - 15.01pm 26/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |